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2Abstract
CD157/BST1 glycosylphosphatidylinositol-anchored glycoprotein is an evolutionary conserved 
dual-function receptor and β-NAD+-metabolizing ectoenzyme of the ADP-ribosyl cyclases gene 
family. Identified as bone marrow stromal cell and myeloid cell differentiation antigen, CD157 turned 
out to have a wider expression than originally assumed. The functional significance of human CD157 
as an enzyme remains unclear, while it was well established in mouse models. Conversely, the 
receptor role of CD157 has been clearly delineated. In physiological conditions, CD157 is a key 
player in regulating leukocyte adhesion, migration and diapedesis. Underlying these functional roles 
is the ability of CD157 to bind with high affinity selected extracellular matrix components within 
their heparin-binding domains. CD157 binding to extracellular matrix promotes its interaction with 
β1 and β2-integrins and induces the organization of a multimolecular complex that is instrumental to 
the delivery of synergistic outside-in signals leading to optimal cell adhesion and migration, both in 
physiological and in pathological situations. CD157 also regulates cell adhesion and migration and is 
a marker of adverse prognosis in epithelial ovarian cancer and pleural mesothelioma.
This review focuses on human CD157 expression and functions and provides an overview on its role 
in human pathology and its emerging potential as target for antibody-mediated immunotherapy.
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31. Introduction
    CD157 has been discovered in 1985 as the Mo5 human myelomonocytic differentiation antigen 
[1]. A decade later, CD157 was identified and characterised as a cell surface receptor expressed in 
bone marrow stromal cells where it supports the growth of hematopoietic B cell progenitors, hence 
the name bone marrow stromal cell antigen 1 (BST1)[2] [3]. Subsequently, the Human Cell 
Differentiation Molecules organization (HCDM; www.hcdm.org) grouped together Mo5 and BST1 
as CD157 cell differentiation marker. Human CD157 is a glycosylphosphatidylinositol (GPI)-
anchored glycoprotein conserved among vertebrates, that along with its paralogue CD38, constitutes 
the ADP-ribosyl cyclases (ARC) gene family [4]. CD157 and CD38 genes maps to human 
chromosome 4 (4p15.33) and they show highly conserved exon structure and gene regulatory 
elements [5]. Until recently, only one BST1 gene consisting of nine exons and eight introns was 
known, which encodes the canonical CD157/BST1 protein of 318 amino acids [4]. Recently, our 
group discovered a second BST1 transcript, which encompasses an additional exon, located between 
exons 1 and 2 of the canonical BST1 gene, and encodes a novel CD157 proteoform (namely, CD157-
002) of 333 amino acids. This unexpected finding unveiled that canonical CD157 does not derive by 
constitutive splicing of the 9-exon BST1 gene as believed, but is generated by exclusion of the 
additional exon by alternative splicing [6]. So far, human CD157 is the first member of the ARC 
family to be described as being regulated by alternative splicing.
    Several single-nucleotide polymorphisms (SNPs) at BST1 gene have been described, four of which 
(i.e., rs11931532, rs12645693, rs4698412 and rs4538475) were identified as risk factors in sporadic 
late-onset Parkinson disease in a Japanese GWA study, with rs4538475 showing the strongest 
association [7]. This association was confirmed in the northern Han Chinese population [8], while it 
was controversial in the European population [9, 10]. Moreover, rs4301112 and rs28532698 SNPs at 
BST1 gene proved to be significantly associated with Autism spectrum disorders in a Japanese 
population [11] but not in a Han Chinese population [12], suggesting that the association between 
4BST1 locus and sporadic late-onset Parkinson’s disease or Autism spectrum disorders varies with 
ethnicity. 
    CD157 protein has a molecular weight ranging between 42-50 kDa due to its heterogeneous 
glycosylation patterns [13]. CD157 exists both as membrane-bound and as a soluble protein that is 
measurable in sera [14] and in pleural and peritoneal effusions [15].
Human CD157 is prevalently expressed in cells belonging to the myelomonocytic lineage, especially 
in monocytes, neutrophils and more immature myeloid stages [16], hence its original designation as 
myeloid differentiation antigen. However, CD157 has a wider expression than previously thought; 
indeed, it was also found in vascular endothelium [17] and tissue-resident vascular endothelial stem 
cells [18], mesothelial cells [19], mesenchymal stem cells [20], follicular dendritic cells [21] and 
Paneth cells [22], and in many other cell types [23-31]. However, functional implications of CD157 
in many of these tissues have not been fully examined. Over the past decade, we have found CD157 
expression in epithelial ovarian cancer [32] and malignant pleural mesothelioma (MPM) [33], and in 
both tumor types a correlation emerged between CD157 expression levels and tumor aggressiveness. 
The expression of CD157 in lymphoid and non-lymphoid tissues is summarized in Table 1.
2. CD157 enzymatic functions
    CD157 shares with CD38 the ability to convert β-NAD+ to cyclic ADP ribose (cADPR, minor 
product) and ADP ribose (APDR, major product), indicating the presence of ADP-ribosyl cyclase, 
NAD glycohydrolase and possibly cyclic adenosine 5′-diphosphoribose hydrolase activities [34, 35]. 
However, human CD157 ADP-ribosyl cyclase activity is hundreds fold less efficient compared to 
that of human CD38, requires an acidic pH (4.0-6.5) and the presence of metal (Zn2+ and Mg2+) ions 
[34, 35]. Actually, CD157 quantitative contribution to generate the intracellular second messenger 
cADPR by β-NAD+ conversion is unknown. In contrast, the β-NAD+ glycohydrolase activity of 
CD157 is readily detectable and leads to production of ADPR, which can act both as a substrate and 
5as a second messenger [36]. Although CD157-002 shares similar distribution and receptor functions 
with canonical CD157, it does not display measurable NADase activity [6].  
    In contrast to what has been observed in human models, in murine models there is evidence that 
cADPR generation by CD157 may be biologically relevant in mediating paracrine signaling in 
hematopoiesis [37], in gut stem cell homeostasis in response to calorie restriction [22] and in social 
behavior, envisaging a role for CD157 as a neuro-entero-immune regulator [38].
3. CD157 receptor functions
    First evidence of the receptor nature of CD157 was inferred from the observation that the protein 
expressed by bone marrow stromal cells supported the growth of a pre-B cell line [3]. Subsequently, 
several experimental evidence confirmed that CD157 behaves as a receptor capable of transducing 
intracellular signals. The receptor functions of CD157 were established long before the discovery of 
its physiological non-substrate ligand, thanks to the availability of specific agonistic (or blocking) 
monoclonal antibodies (mAb). Indeed, binding of CD157 with agonistic antibodies in several 
myelomonocytic cell line models induced tyrosine phosphorylation of a 130 kDa protein, identified 
as focal adhesion kinase (FAK) [39], regulated calcium homeostasis and promoted polarization in 
neutrophils [40], and mediated superoxide (O2-) production in the U937 human myelomonocytic 
leukemia cells [41]. As CD157 lacks intracellular domains, it is unfit to transduce signals by its own. 
To overcame this intrinsic structural limitation, CD157 exploits the lateral mobility provided by the 
GPI-moiety to establish structural and functional interactions with co-receptors in the plasma 
membrane. In particular, in human leukocytes (neutrophils and monocytes), CD157 associates with 
CD29 (β1 integrin) and CD18 (β2 integrin) to form a multimolecular complex mediating out-side-in 
signal transduction [42]. 
    As many other GPI-anchored proteins, CD157 is sorted into specialised cholesterol- and 
ganglioside-enriched microdomains in the cell membrane, referred to as lipid rafts. These membrane 
6domains are dynamic assemblies of proteins and lipids that harbour many receptors and intracellular 
effectors and so act as platforms for signal transduction [43]. Upon binding to its ligand (or 
engagement by a specific mAb as a surrogate for the ligand),  CD157 promotes the recruitment of β1 
and β2 integrin into lipid rafts, thus inducing the formation of a multimolecular complex that delivers 
efficient downstream signals. In leukocytes, CD157-mediated intracellular signals relies on the 
integrin/FAK/Src pathway, leading to increased phosphorylation of tyrosine kinase receptors and 
activation of downstream MAPK/ERK1/2 and PI3K/Akt signaling pathways [44] (Figure 1).
4. CD157 and its natural ligands
    Although it was clear since its discovery that CD157 induces a variety of cellular responses in 
leukocytes and other cell types, apparently unrelated from its enzymatic functions [40], for a long 
time, the efforts to define the non-enzymatic functions of CD157 have been hindered by the lack of 
a known biological ligand. The identification of the role of CD157 in leukocyte adhesion, migration 
and invasion and its functional and structural partnership with β1 and β2 integrins [42, 45], paved the 
way to discover the ability of CD157 to bind with high affinity to selected components of the 
extracellular matrix (ECM) such as fibronectin, fibrinogen, laminin-1 and type 1 collagen (but not 
vitronectin), within their heparin-binding domains [46]. The strong CD157/ECM interaction is 
instrumental to establish a physical interaction with integrins and to deliver intracellular signals 
regulating cell adhesion and migration. Consistently, knockdown of CD157 in myeloid, mesothelial 
or epithelial cells remarkably reduces fibronectin-mediated phosphorylation of FAK, Src, and Akt 
tyrosine kinases [46] and eventually affects cell adhesion and spreading [33, 47]. Overall, 
experimental evidence suggests that binding of human CD157 to selected ECM proteins mediates 
many of the biological effects exerted by CD157 in different physiological (e.g., leukocyte 
trafficking) and pathological contexts (e.g., inflammatory diseases and cancer), where the 
composition of the extracellular matrix in the local environment dictates the proper outcome. For 
7example, in ovarian cancer, the CD157-ECM interaction occurring in the peritoneal cavity rescues 
floating tumor cells from anoikis and promotes their migration and metastatic dissemination, 
ultimately exacerbating tumor aggressiveness [47]. 
    In human mesenchymal stem cells (MSC) CD157 in combination with integrin β1 has been 
reported to act as a receptor for SCRG1 (scrapie responsive gene 1). SCRG1 is a soluble protein 
induced in transmissible spongiform encephalopathies and brain injuries, involved in the regulation 
of MSC self-renewal, migration, and osteogenic differentiation, especially in the central nervous 
system of mice infected with scrapie, where SCRG1 is highly expressed. The SCRG1/BST1/integrin 
axis maintains MSC self-renewal and multipotency and promotes the migration of human bone 
marrow-derived MSC through the activation of the FAK/PI3K/Akt signaling pathway [20]. However, 
functional significance of this interaction in vivo is currently unknown.
5. Role of CD157 in immune response and inflammation
    In the mouse model, ample evidence demonstrated that CD157 is an immunoregulatory molecule 
implicated in early B and T cell growth and development [48]. Moreover, the expression of CD157 
by murine B and T cell progenitors parallels rearrangement of antigen receptor genes [49]. In pro-B 
cells, BST1 is reported as PAX5-activated gene, adding supportive evidence that CD157 functions 
during rearrangement of antigen receptor genes [50]. The murine CD157 KO model highlighted that 
CD157 plays a role in the regulation of the humoral T-independent immune responses and the 
mucosal thymus-dependent response [51]. 
    Our group has spent several years assessing the role of human CD157 in the innate and adaptive 
immune response, coming to the conclusion that CD157 has a key role in the control of myeloid cell 
migration and diapedesis during inflammation, a function which is fully consistent with its expression 
on leukocytes membrane and at intercellular border of vascular endothelial cells, and with its role as 
an adhesion molecule. In the early 2000s, using CD157-specific agonistic (or blocking) mAb, we 
8demonstrated that CD157 regulates neutrophil and monocyte adhesion to ECM proteins and 
orchestrates their motility and transendothelial migration by establishing a structural and functional 
cross-talk with β1- [45] and β2-integrin [40]. These findings were strengthened by the observation 
that neutrophils obtained from patients with paroxysmal nocturnal hemoglobinuria, an acquired 
genetic disease characterized by lack of GPI-anchored molecules, including CD157 [52], are 
characterized by severe defects in neutrophil adhesion, migration and transendothelial migration [17]. 
Hence, blocking CD157 with specific antibodies or its genetic loss, results in impaired cell adhesion 
to ECM proteins and reduced cell motility.
    The discovery that CD157 binds with high affinity to the heparin-binding domains of fibronectin 
or other components of the ECM, revealed the nature of the physiological interaction(s) implementing 
multiple biological activities attributed to CD157 in normal and pathological conditions, unrelated to 
its role as enzyme [32, 33, 46]. 
6. CD157 in pathological conditions
6.1 Autoimmune diseases
6.1.1 Rheumatoid arthritis 
    Several evidence showed that abnormal functions of the bone marrow (BM) play critical roles in 
the pathophysiology of rheumatoid arthritis (RA). Since RA-derived stromal cells express higher 
levels of CD157 than those derived from healthy subjects, it has been hypothesized that CD157 
expressed by synovia-derived stromal cells may contribute to the pathogenesis of the disease by 
increasing the proliferative capacity and reducing apoptosis of pre-B cells [53, 54]. Moreover, soluble 
CD157 concentration in serum from patients with RA proved to be significantly higher than those 
from healthy subjects and to correlate with the severity of the disease [14], hinting to an involvement 
of CD157 in the progression of the disease. However, the mechanistic implication of CD157 in the 
pathophysiology of RA has never been substantiated by experimental evidence.
96.2 Hematologic malignancies
6.2.1 B-cell precursors acute lymphoblastic leukemia
    CD157 has been proposed as marker for disease monitoring in B-cell precursor acute lymphoblastic 
leukemia. Indeed, high CD157 expression discriminates malignant cells from CD157-negative 
normal B cells in the bone marrow from the same patient, and may be useful as an additional marker 
to detect and quantify residual leukemia cells at early treatment time points and during follow-up 
[55].
6.2.2 Acute myeloid leukemia
    Acute myeloid leukemia (AML), the most-common acute leukemia in adults, is a heterogeneous 
disease frequently associated with poor prognosis. Standard chemotherapies can induce complete 
remission in selected patients, however, most patients eventually relapse and succumb to the disease. 
Thus, the development of novel therapies for AML is an urgent need.  The therapeutic 
armamentarium for AML has remained unchanged for decades, until the last two years, when multiple 
drugs with novel mechanisms of action and low toxicity have been approved [56]. Other agents are 
being tested in the clinic, especially  immunotherapeutics, including monoclonal antibodies, chimeric 
antigen receptor-engineered T cells (CART cells), and checkpoint inhibitors [57]. 
CD157 is expressed in 97% of AML patients both at time of primary diagnosis and relapse, regardless 
of the genetic profile. Notably, the highest expression of CD157 is associated to M4 and M5 subtypes 
[58], which represent the group in which conventional chemotherapy has limited efficacy. Albeit at 
lower extent, CD157 was also found in the compartment of leukemia-initiating cells, which are 
believed to be implicated in leukemia relapse [59]. These findings make CD157 an attractive target 
for immunotherapy in AML. To this aim, a novel anti-CD157 monoclonal antibody (MEN1112) has 
been developed by the Menarini Group (Pomezia, Italy) in collaboration with OBT (Oxford Bio 
Therapeutics, Oxon, UK). MEN1112 is a humanized de-fucosylated monoclonal IgG1, which binds 
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to the Fcγ receptor (CD16) on natural killer (NK) cells with enhanced affinity and exerts a robust 
anti-leukemia activity through antibody dependent cell-mediated cytotoxicty (ADCC) [59]. A phase 
I clinical trial is ongoing (NCT02353143).
    Results from various studies convincingly established that the bone marrow (BM) 
microenvironment plays an important role in therapy escape of leukemic cells and occurrence of 
leukemic relapse [60]. Development of novel treatments targeting the cellular and molecular 
mechanisms that control dynamic AML-niche interactions represents an appealing strategy to 
overcome the limitations associated with intrinsic genetic heterogeneity of AML, and to resolve 
niche-mediated drug resistance. By virtue of its expression both by tumor cells and surrounding BM 
stromal cells (BMSC), it is reasonable to predict that CD157 takes part to a positive feedback loop in 
the interactions between AML cells and the BM microenvironment that feeds a ‘vicious cycle’ 
resulting in tumor cell protection from chemotherapy (Figure 2). Our preliminary results obtained in 
vitro from co-culture studies indicated that CD157 expressed by BMSC is involved in the protection 
of primary leukemic cells from the cytotoxic effect of cytosine arabinoside (AraC) treatment (EO and 
SA, personal observation) strengthening the potential clinical utility of CD157 as double therapeutic 
target acting both on leukemia cells and BM niche. 
6.3. Solid tumors
6.3.1. Ovarian cancer
    The expression of CD157 in mesothelial cells [19] on the one hand, and its involvement in the 
control of leukocyte trafficking, on the other, led us to assume that CD157 could be expressed by 
epithelial ovarian cancer cells and could be involved in the control of ovarian cancer dissemination. 
This hypothesis was independently supported by the identification of CD157/BST1 among genes 
overexpressed in primary cultures of epithelial ovarian cancer cells, compared to non-malignant 
epithelial cells [61]. Collectively, our experimental and clinical data demonstrated that CD157 is 
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expressed by more than 90% of epithelial ovarian cancers and is an independent prognostic factor of 
tumor relapse shortly after surgery. In addition, CD157 is involved in the interactions between 
epithelial ovarian cancer cells, ECM proteins and peritoneal mesothelial cells, and through these 
functions it controls tumor cell migration and invasion into surrounding tissues. At the molecular 
level, the functional contribution of CD157 to the progression of epithelial ovarian cancer relies on 
its ability to switch on a differentiation program, which allows neoplastic cells to modulate selected 
genes. This eventually translates into increased expression of protein favoring tumor progression and 
reduced expression of proteins hindering tumor progression, which confers cells a highly malignant 
phenotype, and bring them toward the acquisition of morphological and functional features of 
mesenchymal cells, a prerequisite for cancer cell invasion and metastatic dissemination [47]. 
6.3.2. Malignant Mesothelioma
CD157 is also expressed in >85% of MPM, which share embryonic origin, biologic and phenotypic 
properties and dissemination modalities of epithelial ovarian cancer. Again, high CD157 expression 
proved to be associated with enhanced tumor aggressiveness and shorter survival, notably in patients 
with MPM of biphasic histotype. In vitro, CD157 expression correlates with enhanced cell growth, 
migration, invasion and increased activation of the PI3K/Akt/mTOR pathway and reduced sensitivity 
to platinum-based chemotherapy. These findings are supported by clinical data indicating that patients 
with biphasic MPM and high CD157 expression that received platinum-based therapy had 
significantly shorter survival compared to patients with low CD157 expression [33]. Collectively, 
these data suggest that CD157 has potential clinical utility as a marker for stratifying patients with 
MPM into different prognostic groups. Moreover, CD157 may identify patients with highly 
aggressive MPM, which might benefit from a particular chemotherapeutic approach that may include 
specific inhibitors of the PI3K/Akt/mTOR pathway. Recent results from our group demonstrated that 
soluble CD157 levels is significantly higher in MPM effusions than in all other pleural effusions, 
both non-MPM malignant and non-malignant. Although sCD157 does not have the required accuracy 
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for diagnostic purposes by its own, measurement of effusion sCD157 can provide supporting 
evidence for diagnosing MPM in symptomatic individuals when cytology is inconclusive [15].
7. Conclusion
    CD157 identified over three decades ago as myeloid differentiation marker, has turned out to be a 
key player in the regulation and modulation of various aspect of leukocyte physiology and behavior 
of selected cancer types, hinting to potential clinical applications. Indeed, it is reasonable to envision 
that hindering the interaction between CD157 and fibronectin (or other ECM proteins, depending on 
each specific microenvironment) may represent a new avenue for the design of therapeutic 
approaches against chronic inflammation and cancer. For example, in chronic inflammatory 
conditions, such as arthritis and atherosclerosis, CD157 due to its structural and functional partnership 
with integrins, offers the opportunity for fine-tuning integrin functions avoiding to interfere directly 
with them. Integrins have been a focus of extensive and continuing research as therapeutic targets, 
but despite some outstanding therapeutic successes, the complexity of their function has often made 
treatment development challenging, especially in cancer therapy [62]. Regardless of the encouraging 
in vitro and preclinical results, late phase clinical trials have, thus far, been disappointing. It is possible 
that targeting proteins interacting with integrins, rather than integrins themselves, would be a more 
beneficial therapeutic approach. In ovarian cancer and mesothelioma patients, it is tempting to predict 
that CD157 can be useful as novel marker to formulate prognostic stratification and to refine 
therapeutic selection of patients, and possibly, as novel therapeutic target to counteract invasion and 
dissemination of cancer cells. 
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CD157 expression in healthy tissues
Tissues Cells Ref.
Lymphoid
Blood Neutrophils [40]
Basophils [1]
Monocytes [1]
Macrophages [39]
Plasmocytoid dendritic cells [21]
Bone marrow B cell precursors [25]
Myeloid precursors [1]
Mesenchymal stromal cells [3]
Lymph node Follicular dendritic cells [16]
Spleen Fibroblastic reticular cells (mouse) [23]
Non-lymphoid
Blood vessels Endothelial cells [17]
Tissue-resident vascular endothelial stem cells (mouse) [18]
Mast cells [24]
Liver Fetal B cell progenitors (mouse) [25]
Lung Stem cells (mouse) [26]
Gut Brush border, epithelial cells of villi (rat) [27]
Paneth cells [22]
Stromal cells in cryptopatches and lymphoid follicles and Peyer’s 
patches (mouse) 
[28]
Brain Amygdala, somatosensory cortex (mouse) [38]
Peritoneum Mesothelial cells [19]
Pancreas α and β-cells [29]
Kidney Collecting tubuli (mouse) [30]
Eye Corneal limbal cells, corneal stem cells [31]
CD157 expression in disease conditions
Blood malignancies Acute myeloid leukemia [59]
B-cell precursor acute lymphoblastic leukemia [55]
Autoimmune diseases Nurse-like synovial cells in rheumatoid arthritis [53]
Ovarian cancer Epithelial ovarian cancer cells [32]
Mesothelioma Epithelioid, biphasic and sarcomatoid pleural mesothelioma [33]
Table 1. Expression of CD157 in lymphoid and non-lymphoid tissues, in normal and pathological 
conditions.
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Figure legends
Figure 1. Schematic representation of CD157-mediated intracellular signals. Binding of CD157 
to fibronectin is instrumental to form a multimolecular complex with integrins and to promote the 
assembly of a network of interconnected intracellular signals leading to optimal cell adhesion, 
migration and survival (red arrows) and counteracting cell apoptosis (blue arrows).
Figure 2. Implication of CD157 in the protective effect of bone marrow microenvironment on 
AML cells. AML cells interact with bone marrow stromal cells (BMSC) and extracellular matrix 
proteins (such as, fibronectin) via adhesion molecules. CD157 expressed by AML cells and BMSC 
bind to the heparin binding domain (in red) of selected extracellular matrix components secreted both 
by tumour cells and stromal cells. Cell-cell interaction is potentiated by integrins, which bind both 
ECM proteins (at their cell binding domain, in yellow) and membrane receptors expressed by BMSC, 
such as vascular cell adhesion protein 1 (VCAM-1). These interactions between AML cells and 
BMSC trigger intracellular signals which protect tumor cells from apoptosis, promote cell survival, 
and eventually confer drug resistance to the tumor. Therapeutic strategies that target these interactions 
would reduce the emergence of acquired resistance.
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